Dear Stakeholders,
With its roots going back to a small pharmacy established by Pharmacist Abdi İbrahim Bey in the Küçükmustafapaşa district of Istanbul in 1912, Abdi İbrahim continues its 112-year-long healing journey with courage, passion and a great sense of responsibility, driven for serving humanity.
At Abdi İbrahim, a company with 100 percent domestic capital, we consider our future and the future of our country as one and cement each of our steps for growth on the belief that we add value to our own brand as well the branding of Türkiye. Actually, Abdi İbrahim proudly played a pioneering role for Türkiye in 2020. We acquired OM Pharma, one of the leading biopharmaceutical companies in Switzerland, with a Swiss joint venture group, making Abdi İbrahim the first Turkish pharmaceutical company in history to form a strategic partnership with a Western pharmaceutical company. We were honored to strongly represent our industry in the international arena with this partnership, marking a significant milestone towards our goal of becoming a global player in pharmaceuticals, especially against the highly challenging backdrop of the pandemic.
It was Abdi İbrahim’s strong leadership position within the industry and the sustainable success that it has perpetuated to this day that enabled the company to take these bold steps. Thanks to our continuous investments, state-of-the-art production facilities and strong human resource, we currently work with nearly 30 licensors as well as developing our own products. We boast the most extensive product portfolio in the industry, with more than 250 brands and over 500 products. Having maintained our leadership position within the industry in terms of unit sales and turnover since 2002, we are 5,500 employees strong as we take on the responsibility of healing life across more than 70 countries, from EU states to Canada, North Africa to Asia.
We have maintained our growth-oriented mindset since our inception, persevering through crises by seizing opportunities for growth and leading the charge in many areas within our industry. We continue to further our investments even in the most challenging times with a strong belief in the potential of the Turkish pharmaceutical industry we helped build and in the strength and bright future of our country. Leveraging our ability to devise long-term strategic plans and seize opportunities, as well as our agile response capability in the face of threats, we always take firm steps towards achieving our goals.
We have based our 2025 strategic goals on these values that we consider define us as a company. For the coming period, our eyes are fixed on achieving the level of growth that will help us further bolster our leadership in Türkiye, as well as increasing our international footprint. Our three key areas of growth will be consumer health, production services and biotechnology.
In addition to investments, employment, R&D, collaborations and business partnerships, sustainability is also a crucial item on our agenda. We feel responsible for contributing to a healthier society and a more livable world. Based on this approach, we see a symbiotic relationship between our sustainability strategy and business strategy, where they complement and further enhance one another. As part of our main principle of "healing life", we attach equal importance to the financial, social and environmental outcomes of our operations, and thus shape all our activities and goals for the next period accordingly.
Every success we achieve and every goal we reach further motivates and drives us to work and succeed for our company, industry and country. With a strong commitment to maintaining our success in Türkiye and to becoming a powerful international brand, we are firmly focused on bettering ourselves in generating value every single day.
With a view to becoming a stronger Abdi İbrahim inside and outside Türkiye in the coming period, we will continue healing lives with courage, passion and a great sense of responsibility.
Kind regards,
Nezih Barut
Chairman
